Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00195546
Status:
COMPLETED
Last Update Posted:
2007-06-01
First Post:
2005-09-13
Brief Title:
Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A Multicenter Randomized Double-Blind Placebo- and Active-Controlled Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause
Status:
COMPLETED
Status Verified Date:
2007-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary To assess the efficacy and safety of DVS-233 SR compared with placebo for treatment of vasomotor symptoms VMS associated with menopause and to compare the bleeding incidence of DVS-233 SR and tibolone Secondary To assess the effects of DVS-233 SR and tibolone on changes from baseline in weight breast pain and health outcomes indicators
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None